Tag #Oncology

Showing 25 to 36 of 75 results

pda.vrn.kp.ru

🌐 75% Global Worthiness

May 29, 16:12

Voronezh Oncology Center Warns of Laryngeal Cancer Risks

The Voronezh Regional Oncology Center warns of laryngeal cancer, highlighting risk factors (smoking, alcohol, occupational hazards, HPV, poor diet, chronic conditions) and symptoms (hoarseness, throat pain, cough, breathing difficulties). Prevention focuses on lifestyle changes and early detection.

Voronezh Oncology Center Warns of Laryngeal Cancer Risks

The Voronezh Regional Oncology Center warns of laryngeal cancer, highlighting risk factors (smoking, alcohol, occupational hazards, HPV, poor diet, chronic conditions) and symptoms (hoarseness, throat pain, cough, breathing difficulties). Prevention focuses on lifestyle changes and early detection.

Progress

0% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the most significant risk factors for laryngeal cancer, and what immediate actions can individuals take to mitigate their risk?

Laryngeal cancer, a malignant tumor affecting the larynx, significantly impacts breathing, voice, and swallowing. The Voronezh Regional Oncology Center highlights prevention, especially for high-risk individuals, emphasizing that simple precautions and health awareness reduce the risk.

es.euronews.com

🌐 85% Global Worthiness

May 11, 04:09

Early-Onset Cancer Rates Surge in US, Sparking Urgent Research

A US government study found a significant increase in early-onset cancers (15–49 years) between 2010 and 2019, with the most substantial rises in breast, colorectal, kidney, and uterine cancers, affecting women disproportionately (63%).

Early-Onset Cancer Rates Surge in US, Sparking Urgent Research

A US government study found a significant increase in early-onset cancers (15–49 years) between 2010 and 2019, with the most substantial rises in breast, colorectal, kidney, and uterine cancers, affecting women disproportionately (63%).

Progress

24% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the potential contributing factors to the rising rates of early-onset cancers, and how do these factors vary across different cancer types?

This study highlights a substantial increase in early-onset cancers, exceeding expected rates based on 2010 data. For example, there were approximately 4,800 extra breast cancer cases in 2019. While mortality rates remained stable for most cancers, increases were noted for colorectal, uterine, and testicular cancers, necessitating further investigation into underlying causes.

pda.kp.ru

🌐 85% Global Worthiness

May 1, 01:17

White Nights 2025" Oncology Forum: Global Collaboration for Cancer Care

The 11th St. Petersburg International Oncology Forum "White Nights 2025" will take place in St. Petersburg from July 2nd to 5th, 2025, bringing together oncologists from 29 countries to discuss advancements in cancer treatment and digital innovations, aiming to improve cancer care and reduce mortali...

White Nights 2025" Oncology Forum: Global Collaboration for Cancer Care

The 11th St. Petersburg International Oncology Forum "White Nights 2025" will take place in St. Petersburg from July 2nd to 5th, 2025, bringing together oncologists from 29 countries to discuss advancements in cancer treatment and digital innovations, aiming to improve cancer care and reduce mortali...

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the forum's focus on collaboration between international experts contribute to addressing the global challenge of cancer, and what are the specific outcomes expected?

Building on its success since 2015, the forum's growth reflects the increasing global collaboration needed to combat cancer. The 2024 forum included specialists from Germany, Spain, Turkey, Israel, the USA, China, France, Australia, the UK, and many others, showcasing the international focus on advancements in oncology.

mk.ru

🌐 85% Global Worthiness

Apr 30, 10:11

Exercise Shown to Significantly Reduce Cancer Treatment Side Effects

A large-scale review of 80 studies, published in the British Journal of Sports Medicine, found that physical exercise significantly reduces cancer treatment side effects, improving patients' quality of life and long-term health.

Exercise Shown to Significantly Reduce Cancer Treatment Side Effects

A large-scale review of 80 studies, published in the British Journal of Sports Medicine, found that physical exercise significantly reduces cancer treatment side effects, improving patients' quality of life and long-term health.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key findings of the most comprehensive review to date on the impact of exercise on cancer patients' health outcomes?

A comprehensive review published in the British Journal of Sports Medicine reveals that exercise significantly reduces cancer treatment side effects. The study, involving 485 reviews from 80 articles, showed exercise mitigated chemotherapy-related cardiotoxicity, neuropathy, and cognitive impairment (brain fog). Improvements in sleep quality, psychological well-being, and overall quality of life were also observed.

abcnews.go.com

🌐 90% Global Worthiness

Apr 29, 04:13

Immunotherapy Eliminates Surgery Need in Some Early-Stage Cancers

A new study in the New England Journal of Medicine shows that dostarlimab immunotherapy eliminated the need for surgery in 82 of 103 patients with early-stage cancers with a specific genetic defect; 49 rectal cancer patients avoided surgery, with 92% remaining cancer-free after two years.

Immunotherapy Eliminates Surgery Need in Some Early-Stage Cancers

A new study in the New England Journal of Medicine shows that dostarlimab immunotherapy eliminated the need for surgery in 82 of 103 patients with early-stage cancers with a specific genetic defect; 49 rectal cancer patients avoided surgery, with 92% remaining cancer-free after two years.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the study's findings on early-stage cancer treatment, specifically regarding the need for surgery?

A new study reveals that 82 out of 103 patients with early-stage cancers, possessing a specific genetic alteration, responded remarkably to dostarlimab immunotherapy, eliminating the need for surgery. This impacted 49 rectal cancer patients, all avoiding surgery and showing 92% remaining cancer-free after two years. Among other cancer types, 35 of 54 patients were cancer-free after immunotherapy, avoiding surgery.

lemonde.fr

🌐 85% Global Worthiness

Apr 26, 07:14

Keytruda's $30 Billion Success: Revolutionizing Cancer Treatment

Keytruda, Merck's immunotherapy drug, generated nearly $30 billion in 2024 sales, marking a paradigm shift in cancer treatment since its 2014 launch, building upon research dating back to the late 19th century.

Keytruda's $30 Billion Success: Revolutionizing Cancer Treatment

Keytruda, Merck's immunotherapy drug, generated nearly $30 billion in 2024 sales, marking a paradigm shift in cancer treatment since its 2014 launch, building upon research dating back to the late 19th century.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the global significance of Keytruda's financial success and its impact on cancer treatment?

Keytruda, Merck Sharp and Dohme's cancer drug, generated over $130 billion in revenue since its 2014 launch, reaching nearly $30 billion in 2024 sales. This success is attributed to its pioneering role in immunotherapy, a revolutionary approach compared to traditional chemotherapy.

smh.com.au

🌐 85% Global Worthiness

May 25, 13:11

New Bladder Cancer Treatment Offers Hope in Australia

A new combined chemotherapy treatment for bladder cancer is being rolled out in Australian hospitals, offering a significant improvement in survival rates for patients with aggressive cancers in the lining of the bladder who are unsuitable for surgery or immunotherapy, with a 60-69% success rate rep...

New Bladder Cancer Treatment Offers Hope in Australia

A new combined chemotherapy treatment for bladder cancer is being rolled out in Australian hospitals, offering a significant improvement in survival rates for patients with aggressive cancers in the lining of the bladder who are unsuitable for surgery or immunotherapy, with a 60-69% success rate rep...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

Why have bladder cancer survival rates in Australia declined in recent years, and how does this new treatment address these challenges?

The success of this new treatment, involving two affordable chemotherapy drugs, is linked to the limitations of existing methods. Immunotherapy's ineffectiveness in 30-50% of patients highlights a critical unmet need addressed by this combined approach, which showed 60-69% success in a trial of 19 patients at Monash Health, based on a larger US study. This improved effectiveness, coupled with reduced side effects, changes established treatment protocols.

welt.de

🌐 85% Global Worthiness

May 5, 16:13

BioNTech's Oncology Push: Cancer Drug Filing Planned, Q1 Loss Reported

BioNTech, experiencing a €415.8 million net loss in Q1 2025, plans to file for U.S. approval of a uterine cancer treatment by year-end, aiming to become a leading oncology company by 2030, with a new CFO starting July 1st, 2025.

BioNTech's Oncology Push: Cancer Drug Filing Planned, Q1 Loss Reported

BioNTech, experiencing a €415.8 million net loss in Q1 2025, plans to file for U.S. approval of a uterine cancer treatment by year-end, aiming to become a leading oncology company by 2030, with a new CFO starting July 1st, 2025.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does BioNTech's Q1 2025 financial performance relate to its long-term oncology goals?

This filing represents BioNTech's strategic shift towards oncology, aiming for multiple cancer treatments by 2030. The Q1 2025 loss reflects substantial investment (€525.6 million) in advanced clinical trials for various cancer types, supporting their goal of becoming a leading biotech company in oncology. Revenue slightly decreased to €182.8 million compared to the previous year due to seasonal Covid-19 vaccine demand.

dw.com

🌐 85% Global Worthiness

May 1, 01:16

Exercise Significantly Reduces Cancer Treatment Side Effects, Improves Well-being: Study

A study published in the British Journal of Sports Medicine on April 30, 2025, reveals that exercise significantly reduces cancer treatment side effects, improves mental and physical well-being, and enhances social interaction among patients, based on an analysis of 80 systematic reviews.

Exercise Significantly Reduces Cancer Treatment Side Effects, Improves Well-being: Study

A study published in the British Journal of Sports Medicine on April 30, 2025, reveals that exercise significantly reduces cancer treatment side effects, improves mental and physical well-being, and enhances social interaction among patients, based on an analysis of 80 systematic reviews.

Progress

24% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key benefits of exercise for cancer patients undergoing treatment, based on the recent British Journal of Sports Medicine study?

A study in the British Journal of Sports Medicine indicates that exercise can significantly reduce cancer treatment side effects, improve mental well-being, and enhance sleep quality. Researchers analyzed 80 systematic reviews showing exercise lessened cardiac and nerve damage, brain fog, and other side effects. Patients reported better quality of life.

foxnews.com

🌐 92% Global Worthiness

Apr 29, 01:17

Immunotherapy Shows 80% Success Rate in Treating Various Cancers

A Memorial Sloan Kettering study published in The New England Journal of Medicine reveals that immunotherapy successfully treated 80% of patients with various cancer types, including 100% of rectal cancer patients, offering a less toxic alternative to traditional treatments.

Immunotherapy Shows 80% Success Rate in Treating Various Cancers

A Memorial Sloan Kettering study published in The New England Journal of Medicine reveals that immunotherapy successfully treated 80% of patients with various cancer types, including 100% of rectal cancer patients, offering a less toxic alternative to traditional treatments.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of this immunotherapy treatment's success on cancer care, especially for those with MMRd-positive tumors?

A new immunotherapy treatment shows significant promise, achieving an 80% success rate across various cancer types in a Memorial Sloan Kettering study published in The New England Journal of Medicine. Rectal cancer patients saw a 100% success rate, avoiding the harsh side effects of traditional treatments like surgery, chemotherapy, and radiation. This success offers a life-changing alternative for many.

dailymail.co.uk

🌐 90% Global Worthiness

Apr 28, 04:12

Pembrolizumab Extends Head and Neck Cancer Remission by 30 Months

A global phase III trial involving 714 patients with newly diagnosed head and neck cancer showed that pembrolizumab combined with standard treatment significantly increased disease-free survival to 60 months compared to 30 months for standard treatment alone.

Pembrolizumab Extends Head and Neck Cancer Remission by 30 Months

A global phase III trial involving 714 patients with newly diagnosed head and neck cancer showed that pembrolizumab combined with standard treatment significantly increased disease-free survival to 60 months compared to 30 months for standard treatment alone.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the pre- and post-surgical administration of pembrolizumab contribute to the observed improvements in patient outcomes?

The trial's success stems from using pembrolizumab pre- and post-surgery, priming the immune system to attack cancer cells more effectively. This approach significantly increases the chance of remaining disease-free, with 58% of pembrolizumab patients disease-free after three years compared to 46% in the control group. The improved outcomes are observed across all tumor types.

pda.saratov.kp.ru

🌐 75% Global Worthiness

Apr 24, 10:14

Saratov Opens State-of-the-Art Oncology Center

Saratov's new clinical oncology center, supported by State Duma Chairman Vyacheslav Volodin, opened its doors, boasting advanced equipment, performing up to 60 surgeries daily and already treating over 13,000 patients, with plans for expansion and attracting medical professionals from other regions.

Saratov Opens State-of-the-Art Oncology Center

Saratov's new clinical oncology center, supported by State Duma Chairman Vyacheslav Volodin, opened its doors, boasting advanced equipment, performing up to 60 surgeries daily and already treating over 13,000 patients, with plans for expansion and attracting medical professionals from other regions.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the new oncology center in Saratov on cancer care in the region?

A new clinical oncology center in Saratov, Russia, supported by State Duma Chairman Vyacheslav Volodin, has opened and is fully operational. It features 9 operating rooms (3 small, 6 large) capable of 60 surgeries daily and advanced equipment including MRI and CT scanners. The center has already seen over 13,000 patients since opening.

Showing 25 to 36 of 75 results